We have previously described that clearance of tumor-derived soluble NKG2D ligands, sMIC, with a monoclonal antibody (mAb) B10G5 restores NK cell homeostatic renewal, enhances NK cell and antigen-specific CD8 T cell function, immobilizes NK and CD8 T cell to the tumors, and re-modulates tumor microenvironment by eliminating MDSCs and tumor-associated macrophages [17, 18]. The gene discussed is CD8A; the disease is neoplasm.